SPRO
SPRO
NASDAQ · Biotechnology

Spero Therapeutics Inc

$2.25
+0.01 (+0.45%)
As of Mar 31, 3:11 PM ET ·
Financial Highlights (FY 2026)
Revenue
50.02M
Net Income
-71,483,302
Gross Margin
Profit Margin
-142.9%
Rev Growth
+38.0%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 49.6% 49.6%
Operating Margin -152.9% -137.6% -22.5% -21.2%
Profit Margin -142.9% -135.8% -19.0% -18.7%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 50.02M 36.25M 30.93M 26.54M
Gross Profit 15.33M 13.15M
Operating Income -76,482,568 -49,883,550 -6,967,592 -5,637,171
Net Income -71,483,302 -46,622,923 -5,880,957 -4,950,304
Gross Margin 49.6% 49.6%
Operating Margin -152.9% -137.6% -22.5% -21.2%
Profit Margin -142.9% -135.8% -19.0% -18.7%
Rev Growth +38.0% +38.0% +18.4% +23.2%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 26.75M 29.13M
Total Equity 80.40M 90.84M
D/E Ratio 0.33 0.32
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -76,418,625 -52,610,836 -8,827,347 -7,842,890
Free Cash Flow -6,633,459 -6,096,996